共 50 条
- [3] Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (03): : 205 - 215
- [4] Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 874 - 882
- [5] Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study [J]. DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1136 - 1145
- [6] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
- [8] Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2954 - 2962